Hellenic Journal of Nuclear Medicine This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Quality assurance in clinical dosimetry
CONCLUSION: Nuclear medicine dosimetry quality assurance (QA) is in its infancy. However, procedures already applied in external beam radiotherapy may be easily transposed to nuclear medicine, and it will not take decades until nuclear medicine benefits from sound, reproducible procedures that will increase the robustness of clinical dosimetry procedures.PMID:37658553 (Source: Hellenic Journal of Nuclear Medicine)
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Manuel Bardi ès Source Type: research

Dosimetry in MRT: Our recent experience
DISCUSSION: According to our experience, different fitting of each organ's activity curve, results in differences in the final calculated dose. Use of bi-exponential fitting seems to better approach physical and metabolic decay. Calculated absorbed doses for the OARs were found similar to those expected from literature. Finally, department's future work was discussed, including reproducible patient setup for image acquisition, high dose CT for finer contouring and comparison of the calculated doses with other TPSs.PMID:37658554 (Source: Hellenic Journal of Nuclear Medicine)
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Lydia Angeliki Zoglopitou Source Type: research

Organizing and operating a one day clinic / theragnostic center
Hell J Nucl Med. 2023 May-Aug;26 Suppl:16-18.ABSTRACTThe increasing success of recent nuclear medicine therapies, which followed the NETTER-1 and VISION trials, has boosted the interest for setting up and operating theragnostic centers. EANM, SNMMI and IAEA have recently published a joint guideline in order to assist nuclear medicine centers towards that path. The present paper will focus on the main points of these guidelines, with reference to the Greek radiation protection legislation.PMID:37658555 (Source: Hellenic Journal of Nuclear Medicine)
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Emmanouil Papanastasiou Source Type: research

Radiopharmaceuticals used for diagnosis and therapy of NETs
Hell J Nucl Med. 2023 May-Aug;26 Suppl:19-20.ABSTRACTThe first description of the in vivo visualization of somatostatin receptor-positive tumors in patients was based on the use of a radioiodine (123I) labelled somatostatin analogue (Krenning et al. 1989). In the years that followed an Indium-111 (111In) labelled somatostatin analogue, chelated with diethylenetriaminepentaacetic acid (DTPA), was successfully developed. Subsequently, 111In-OctreoScan was introduced worldwide. In the years to come 99mTc-Tektrotyde became commercially available with easy access. In the last decade, with the increasing use of positron emission...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Maria Papachristou Source Type: research

Lung cancer: CT guided BX-EBUS: How and when?
Hell J Nucl Med. 2023 May-Aug;26 Suppl:21.ABSTRACTHistological diagnosis is mandatory for the majority of solid lesions in the lungs in order to characterize the lesions but also to assess the response to treatment. Flexible bronchoscopy has a variable and often poor success rate in sampling pulmonary lesions which are not visible endoscopically. Such focal radiological opacities without endobronchial extension are referred to as peripheral pulmonary lesions and sampling is usually performed under guidance with computed tomography that is a safe and effective technique and became a common procedure representing an essentia...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Miltiadis Krokidis Source Type: research

The role of positron computed tomography (PET/CT) in lung cancer staging
Hell J Nucl Med. 2023 May-Aug;26 Suppl:22-29.ABSTRACTLung cancer is the leading cause of cancer-related mortalities with the rate of incidence reaching about 1.5 million cases per year worldwide. Approximately 350 people die each day from lung cancer in USA-nearly 2.5 times more than the number of people who die from colorectal cancer (CRC), which is the second leading cause of cancer death overall. In 2023, an estimated 238,340 people (117,550 men and 120,790 women) will be diagnosed with lung cancer, and 127,070 people will die from the disease. Although approximately 80% of lung cancers are caused by cigarette smoking, ...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Emmanouil Panagiotidis Source Type: research

The progress in multiple myeloma
Hell J Nucl Med. 2023 May-Aug;26 Suppl:30-35.ABSTRACTMultiple myeloma (MM) is a neoplastic disease characterized by the proliferation of clonal plasma cells. This disease arises from an initial asymptomatic stage known as monoclonal gammopathy of unknown significance (MGUS). The clinical phenotype that lies between MGUS and MM is commonly known as smoldering multiple myeloma (SMM). In individuals with MGUS and SMM, the risk of progression to MM persists constantly. In MGUS, the progression rate to MM or a related malignancy is around 1% per year, while in SMM, the progression rate to MM is approximately 10% per year. Recen...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: P Hatjiharissi Source Type: research

PET/CT: Clinical role in lymphomas
Hell J Nucl Med. 2023 May-Aug;26 Suppl:36-37.ABSTRACT18F-FDG PET/CT is the imaging modality of choice for the accurate initial staging of most lymphomas. Hodgkin's, Diffuse Large B-cell and follicular lymphomas show avid FDG uptake, while a minority of Non-Hodgkin lymphoma subtypes namely MALT, marginal and small lymphocytic lymphoma demonstrate low or moderate avidity. As a rule of thumb, indolent lymphomas show lower FDG activity than aggressive ones. PET/CT has increased sensitivity in the detection of nodal involvement even in small or normal-sized nodes. It shows higher sensitivity than CT in the detection of extra-no...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Nikolaos Papathanasiou Source Type: research

< sup > 18 < /sup > F-FDG PET/CT in monoclonal plasma cell disorders
Hell J Nucl Med. 2023 May-Aug;26 Suppl:38-41.ABSTRACTPlasma cell disorders are a heterogeneous group caused by the monoclonal proliferation of lymphoplasmacytic cells in the bone marrow. Multiple Myeloma (MM) is the most serious and prevalent plasma cell dyscrasia, with a median age of onset of 60 years.MM displays significant genetic, biological and clinical heterogeneity with subsequent imaging heterogeneity, evident in contemporary imaging modalities (PET/CT and MRI). Evidence suggests that MM is always preceded by precursor stages of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myel...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Anna Paschali Source Type: research

Theranostic in Nuclear Medicine - The paradigm of NET
Hell J Nucl Med. 2023 May-Aug;26 Suppl:42-43.ABSTRACTTheranostics is an emerging field in medicine that combines diagnostics and therapeutics into a single approach. Overall, theranostics represents a promising paradigm for personalized medicine, as it allows for targeted and precise treatment based on individual patient characteristics. In nuclear medicine, theranostics involves the use of radiopharmaceuticals that have both diagnostic and therapeutic properties. Moreover, theranostics in nuclear medicine offers several advantages over traditional cancer treatments. Unlike radiotherapy, in nuclear medicine the therapy is ...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Francesco Giammarile Source Type: research

Biomarkers in neuroendocrine neoplasms
Hell J Nucl Med. 2023 May-Aug;26 Suppl:44-48.ABSTRACTNeuroendocrine tumors are a heterogenous group of rare neoplasms with different morphological features, immunophenotype, molecular profile, and clinical presentation. They can derive from any neuroendocrine cell throughout the body, but the majority of NENs is developed in the gastrointestinal tract. They can be divided into two groups, based on hormone secretion, functioning and non-functioning NENs. The first group is characterised from the secretion of specific substances, defining the clinical manifestations. Functional NENs can be divided into carcinoid tumors, with...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Chrisanthi Zouli Eleana Zisimopoulou Alexandra Chrisoulidou Source Type: research

Current role of Nuclear Medicine in the diagnosis and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Hell J Nucl Med. 2023 May-Aug;26 Suppl:49-51.ABSTRACTNeuroendocrine tumors (NETs), are heterogenic neoplasms that arise from the disseminated endocrine cell system, primarily from gastroenteropancreatic (GEP) organs. Nuclear Medicine has a central role in both diagnosis and treatment of GEP-NETs. Somatostatin receptor scintigraphy (SRS) is still performed with SPECT/CT in case that PET/CT is not available but numerous studies have demonstrated the superior diagnostic accuracy of the latter for GEP-NETs. 68Ga -Dota peptide PET/CT (SSA-PET/CT) has high sensitivity, specificity and accuracy (86%-100%) and is recommended for t...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Alexandros Georgakopoulos Source Type: research

Carcinoid syndrome-Symptoms and therapeutic approaches
Hell J Nucl Med. 2023 May-Aug;26 Suppl:52-56.ABSTRACTThe carcinoid syndrome (CS) is a constellation of symptoms attributed to hypersecretion of amines, prostaglandins and polypeptides. The cardinal symptoms of CS are flushing, diarrhea and bronchospasm; however, CS may present with various symptoms and signs, as: Skin: cutaneous flushes, cyanosis, pellagra, Gastrointestinal: diarrhea, nausea, abdominal cramps, vomiting, Heart: tricuspid and pulmonic valve thickening causing right heart failure, edema, Respiratory: wheezing, dyspnea.PMID:37658565 (Source: Hellenic Journal of Nuclear Medicine)
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Alexandra Chrisoulidou Source Type: research

Changes in the concept and practice of radioembolization (SIRT)
Hell J Nucl Med. 2023 May-Aug;26 Suppl:57-59.ABSTRACTThe experience gained through the practice of radioembolization (SIRT) results in improvement of clinical outcomes. Improved outcomes are a prerequisite for the clinicians to reffer patients for SIRT. In recent years there are some critical changes in the concept and practice of SIRT that also contribute to the improvement of clinical outcomes, beyond the experience of the center performing SIRT. Two of them are dosimetry and a trend toward more focused therapies in the form of radiation lobectomy or segmentectomy.PMID:37658566 (Source: Hellenic Journal of Nuclear Medicine)
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Trifon Spyridonidis Source Type: research

Management of pediatric papillary thyroid cancer
Hell J Nucl Med. 2023 May-Aug;26 Suppl:60-64.ABSTRACTPapillary thyroid carcinoma (PTC) originates from the follicular cell of the thyroid gland. PTC is a rare cancer and usually develops in pre-existing thyroid nodules, which are not common in children. PTC is often multifocal and bilateral. Low-risk subtypes such as classic PTC and follicular variant account for the majority of PTC, while high-risk histologic subtypes such as tall cell variant, diffuse sclerosing variant and poorly differentiated thyroid cancer occur more rarely in children. It is worth noting that the size of the thyroid in children is smaller compared t...
Source: Hellenic Journal of Nuclear Medicine - September 2, 2023 Category: Nuclear Medicine Authors: Kalliopi Pazaitou-Panayiotou Source Type: research